Top 5 Pharmacy Times Skin Cancer Articles of 2023

1. Monotherapy Pembrolizumab Demonstrates Historic Response for Rare Skin Cancer

The treatment from Merck shows a clinical response of 89% for individuals with unresectable metastatic desmoplastic melanoma. Read More Here.

InsideCreativeHouse - stock.adobe.com

2. ‘Warm’ Autopsy Suggests Metastatic Melanoma Has Different DNA Landscape Than Early-Stage Disease

Findings may offer insight into new strategies to tackle skin cancer in patients already treated with a prior line of therapy. Read More Here.

3. Data Show an Increased Risk of Skin Cancer in Patients with Lower Extremity Lymphedema

According to the authors, these results contribute to developing information that associate lymphedema with localized changes in immunity and a susceptibility to cancer. Read More Here.

4. Study Results Demonstrate Population-Based Effects of [Skin Cancer Screening] on Melanoma Mortality Minimal, Not Significant

The study authors acknowledged that low skin cancer screening (SCS) participation, the participants’ better health than nonparticipants, and examination biases may be contributing factors to the insignificant results. Read More Here.

5. Study Indicates Potential of Pembrolizumab in Advanced Melanoma

A change in recurrence-free survival was also observed, with an 89% rate at 24 months in patients who achieved a complete pathologic response. Read More Here.